Target intelligence / Profile preview

T cell receptor alpha variable 21 (TRAV21)

Target
TRAV21
Molecular classification
Receptor, T cell receptor (variable region of alpha chain), Immunoglobulin superfamily
01

Overview

T cell receptor alpha variable 21 (TRAV21) encodes a variable segment of the T cell receptor (TCR) alpha chain, which is essential for antigen recognition by αβ T cells. The TCR, comprising alpha (TRA) and beta (TRB) chains, recognizes processed foreign antigens presented by major histocompatibility complex (MHC) molecules on antigen-presenting cells, triggering cell-mediated immune responses[1][2]. TRAV21 is one of many gene segments that are somatically recombined during T cell development to yield a diverse repertoire of TCRs, enabling recognition of a vast range of antigens. The variable domain, including CDR (complementarity determining regions), directly interacts with peptide-MHC complexes, contributing to T cell specificity and function[1][3]. While TRAV21 is not a therapeutic target per se, it can play a role in immunotherapies where defined TCR variable regions are engineered for specificity, such as in adoptive T cell therapies[3].

Other names
T cell receptor alpha variable 21TRAV21TCRAV21S1TCRAV23S1
02

Mechanism of action

Not applicable at this resolution (no drugs are known to target TRAV21 specifically; its mechanism is via *antigen recognition* as a TCR alpha variable segment)

03

Biological functions

Antigen recognitionImmune response
04

Disease associations

InfectionOther (potential in cancer and autoimmune conditions, as part of TCR/T cell therapy approaches by specificity)
05

Safety considerations

No specific safety concerns associated with TRAV21 as an isolated recombined segment, but engineering TCRs carries general risks (e.g., off-target effects, autoimmunity)
06

Interacting drugs

None known (TRAV21 is not a classical drug target, but there may be research use in TCR/T cell engineering; TRAV21 itself is not the direct target of drugs)
07

Biomarkers

None known specific to TRAV21

Beyond the preview

Go deeper on T cell receptor alpha variable 21 (TRAV21).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha variable 21 (TRAV21).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call